FasTCAR next-day manufacturing autologous CAR-T platform recognized with prestigious biotech innovation award
FasTCAR enables next-day manufacturing for autologous CAR-T and aims to address major obstacles to effective and accessible cell therapy. By cutting the manufacturing time from weeks to overnight, the FasTCAR platform could potentially revolutionize several key aspects of the CAR-T logistics and treatment paradigm, including bringing therapies to patients more quickly, reducing costs, and providing T cells with enhanced quality that could lead to better outcomes.
Gracell's lead FasTCAR candidate, GC012F, is a CAR-T cell therapy dual-targeting B-cell maturation antigen (BCMA) and CD19. It is currently being studied in multiple investigator-initiated trials evaluating its safety and efficacy in relapsed/refractory multiple myeloma (RRMM), newly-diagnosed multiple myeloma (NDMM), and B-cell non-Hodgkin's lymphoma. At the
The Fierce Life Sciences Innovation Awards identify and showcase outstanding innovation that is driving improvements and transforming the industry. An expert panel of judges reviews all submissions and determines which companies demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma.
"We are honored that the FasTCAR next-day manufacturing platform has been recognized by the prestigious Fierce Life Sciences Innovation Awards," said
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate that is currently being evaluated in IIT studies in
CAR-T cells manufactured on Gracell's proprietary FasTCAR platform appear younger, less exhausted and show enhanced proliferation, persistence, bone marrow migration and tumor cell clearance activities as demonstrated in preclinical studies. With next-day manufacturing, FasTCAR is able to significantly improve cell production efficiency which may result in meaningful cost savings, and, together with fast release time, enables enhanced accessibility of cell therapies for cancer patients.
Cautionary Noted Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled "Risk Factors" in Gracell's most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell's subsequent filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-wins-2022-fierce-life-sciences-innovation-award-301677853.html